In addition to providing the highest-quality testing to patients, Myriad Women’s Health is committed to sharing our discoveries with the scientific community. We publish our clinical and technical advances in peer-reviewed journals and present data at prominent conferences. Through these research endeavors, Myriad Women’s Health has established itself as a trusted thought leader in clinical genomics. Explore the entire archive of our scientific contributions, with highlights of our most recent work.
Head-to-head comparison of genome sequencing methods used for noninvasive prenatal screening (NIPS)
Just published in Prenatal Diagnosis, this comprehensive study examines Whole-Genome Sequencing (WGS) and Single-Nucleotide Polymorphism (SNP) methods, the most common methods used for NIPS.
This study concludes that for patients with low fetal fraction:
- WGS has higher sensitivity and will detect more aneuploidies at low fetal fraction
- WGS leads to fewer no calls, fewer false negatives, and significantly fewer invasive procedures
Trained at the world’s top universities and institutes, scientists and engineers come to Myriad Women’s Health to improve people’s lives using cutting-edge genomics tools. The R&D lab has a diverse talent base, including chemical engineers, theoretical mathematicians, molecular biologists, software developers, robotics experts, and bioinformaticians.
We combine our skill sets on team-based projects to create superior clinical DNA testing technology.
Interested in joining our team?